Axilyta 5 – Advancing Care in Renal Oncology
Product Launch Announcement: Axilyta 5 (Axitinib 5mg) Tablet We are proud to introduce Axilyta 5 is a targeted oral anti-cancer therapy containing Axitinib 5mg, designed for the effective management of advanced renal cell carcinoma. As a potent and selective tyrosine kinase inhibitor, Axilyta 5 helps inhibit tumor angiogenesis, slowing disease progression and improving clinical outcomes. 🔍…
